Why the study?
Beta-blockers have not been shown to improve mortality or reduce hospital admissions in heart failure patients with atrial fibrillation.
Does beta-blocker therapy at discharge improve mortality or reduce hospital admissions in patients with acute heart failure and atrial fibrillation?
Population
936 HFrEF and 639 HFpEF patients with AF from the Korean Acute Heart Failure Registry
Comparison
Beta-blockers at discharge vs untreated
Design
Propensity score-matched registry cohort study
Follow-up
1 year
Authors
Loading...
May reduce rehospitalization in HFpEF-AF; hypothesis-generating and requires RCT confirmation before practice change.
Does beta-blocker therapy at discharge improve mortality or reduce hospital admissions in patients with acute heart failure and atrial fibrillation?
Beta-blocker therapy at discharge in patients with acute heart failure and atrial fibrillation is associated with reduced rehospitalization in HFpEF, but shows no clinical benefit in HFrEF.
Ahn et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: